Details

Autor(en) / Beteiligte

• Valente, Stephanie A.
• Tendulkar, Rahul D.
• Cherian, Sheen
• Shah, Chirag
• Ross, Darrel L.
• Lottich, S. Chace
• Laronga, Christine
• Broman, Kristy K.
• Donnelly, Eric D.
• Bethke, Kevin P.
• Shaw, Christina
• Lockney, Natalie A.
• Pederson, Aaron
• Rudolph, Ray
• Hasselle, Michael
• Kelemen, Pond
• Hermanto, Ulrich
• Ashikari, Andrew
• Kang, Song
• Hoefer, Richard A.
• McCready, David
• Fyles, Anthony
• Escallon, Jamie
• Rohatgi, Nitin
• Graves, Jeannine
• Graves, Gregory
• Willey, Shawna C.
• Tousimis, Eleni
• Riley, Lee
• Deb, Nimisha
• Tu, Chao
• Small, William
• Grobmyer, Stephen R.

Titel

TARGIT-R (Retrospective): 5-Year Follow-Up Evaluation of Intraoperative Radiation Therapy (IORT) for Breast Cancer Performed in North America

Ist Teil von

• Annals of surgical oncology, 2021-05, Vol.28 (5), p.2512-2521

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Intraoperative radiation therapy (IORT) has been investigated for patients with low-risk, early-stage breast cancer. The The North American experience was evaluated by TARGIT-R (retrospective) to provide outcomes for patients treated in “real-world” clinical practice with breast IORT. This analysis presents a 5-year follow-up assessment. Methods TARGIT-R is a multi-institutional retrospective registry of patients who underwent lumpectomy and IORT between the years 2007 and 2013. The primary outcome of the evaluation was ipsilateral breast tumor recurrence (IBTR). Results The evaluation included 667 patients with a median follow-up period of 5.1 years. Primary IORT (IORT at the time of lumpectomy) was performed for 72%, delayed IORT (after lumpectomy) for 3%, intended boost for 8%, and unintended boost (primary IORT followed by whole-breast radiation) for 17% of the patients. At 5 years, IBTR was 6.6% for all the patients, with 8% for the primary IORT cohort and 1.7% for the unintended-boost cohort. No recurrences were identified in the delayed IORT or intended-boost cohorts. Noncompliance with endocrine therapy (ET) was associated with higher IBTR risk (hazard ratio [HR], 3.67). Patients treated with primary IORT who were complaint with ET had a 5-year IBTR rate of 3.9%. Conclusion The local recurrence rates in this series differ slightly from recent results of randomized IORT trials and are notably higher than in previous published studies using whole-breast radiotherapy for similar patients with early-stage breast cancer. Understanding differences in this retrospective series and the prospective trials will be critical to optimizing patient selection and outcomes going forward.